Tagged with VAT

Pharma A leading consultant to IMS and Professor at Paris Dauphine University reveals how the French healthcare system is moving in two main strategic directions: increasingly relying on private funding through complementary health insurance, and breaking with the egalitarian principle that everybody should be reimbursed to the same extent irrespective of…

Pharma Egypt is at the ‘golden stage’ for investment, claims Boehringer Ingelheim country head Mohamed El-Sahhar, who explains how the company is expanding their organization in Egypt ahead of an expansion into diabetes and oncology.  Egypt’s international image is still heavily influenced by the political instability of 2011 to 2013; what…

Pharma Prof. Walter Ricciardi has just been appointed as the new president for the Italian National Institute of Health (ISS). He explains his priorities since taking office, the crucial role the ISS plays in the NHS and his vision for the future of the Italian National Healthcare System. Prof. Ricciardi, can…

Pharma Maikel Beerens, CEO and founder of Xilloc, a promising Dutch company that designs patient-specific implants, anatomical models and surgical guides for bone reconstruction or augmentation with the help of 3-D printing, explains how his company aims to provide patients worldwide with the tailor-made implants they deserve while reducing the overall socio-economic cost…

Pharma Menno Kok and Roel Kamerling, Director and CIO of Medical Delta, a life sciences, health & technology innovation cluster around Leiden, Delft and Rotterdam in the West of the Netherlands, explains how this network aims to stimulate economic growth and provide healthcare solutions by developing, transferring and implementing knowledge in…

Pharma Paolo Cionini, General Manager of LEO Pharma Italy, discusses the initial challenges of setting up the Italian affiliate during the height of the global financial crisis in 2011, the company’s management culture, their emphasis on patient-centricity and holistic patient care, as well as the importance of maintaining a good relationship…

Pharma Marc-Antoine Lucchini, the president-general manager of Sanofi France, talks about their unprecedented number of new molecules and innovations soon to be launched. He also explains the need to focus on the long-term impact of pricing and why the way Sanofi performs in France acts as a model for other affiliates across…

Pharma The CEO of Medicen Paris Region, the biopharma cluster for the Paris region, discusses her vision to develop a world-class cluster and act as a catalyst for innovation; her international partnership strategy and how her diverse background in engineering, medicine and a variety of companies has equipped her to lead…

Pharma Bernard Vanhove, CEO and Maryvonne Hiance, Chairman of Effimune, an immune regulation biotech, discuss their novel approach to developing immunotherapies, their partnership and commercialization strategies, their perspective on the landscape of immunotherapy as well as the evolution of the French biotech environment, and finally, their mission to position Effimune as…

Pharma Antonino Reale, who has managed Daiichi-Sankyo Italy for the last 12 years, explains the reasoning and strategy behind the company’s almost total restructuring in 2013, including how this has given birth to a new, more agile organization with high engagement amongst its employees, as well as where he believes the…

Pharma The Italian Medicines Agency, AIFA, sits at a crossroads. Its Director-General Prof. Luca Pani discusses the apparent contradiction in the agency’s mission at a time of constricting budgets and expensive medicines, how the agency’s role is evolving in response and in which ways the agency can collaborate with the industry.…

Pharma Dominique Costantini, the CEO of OSE Pharma, a French biotech company developing immunotherapy products against late-stage (invasive and metastatic) cancer discusses the company’s unique targeted approach based on a patented neo-epitopes combination, its plans to break into the immuno-oncology domain and its perspectives on the French regulatory and biotech environments, and emphasizes…